Assetmark Inc. Has $102,000 Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)

Assetmark Inc. boosted its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTLFree Report) by 21.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,736 shares of the company’s stock after buying an additional 832 shares during the quarter. Assetmark Inc.’s holdings in Castle Biosciences were worth $102,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of CSTL. Principal Financial Group Inc. increased its holdings in shares of Castle Biosciences by 7.0% during the 4th quarter. Principal Financial Group Inc. now owns 1,585,673 shares of the company’s stock worth $34,219,000 after acquiring an additional 103,503 shares during the last quarter. WuXi AppTec Co. Ltd. acquired a new position in shares of Castle Biosciences in the fourth quarter valued at $143,000. Russell Investments Group Ltd. raised its position in shares of Castle Biosciences by 10.3% in the fourth quarter. Russell Investments Group Ltd. now owns 31,983 shares of the company’s stock valued at $690,000 after purchasing an additional 2,998 shares during the period. Knights of Columbus Asset Advisors LLC lifted its stake in shares of Castle Biosciences by 99.2% during the 4th quarter. Knights of Columbus Asset Advisors LLC now owns 106,262 shares of the company’s stock worth $2,293,000 after buying an additional 52,921 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Castle Biosciences by 20.5% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,192 shares of the company’s stock worth $177,000 after buying an additional 1,395 shares during the period. Institutional investors own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on CSTL. Robert W. Baird raised their price objective on shares of Castle Biosciences from $33.00 to $34.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Scotiabank boosted their price target on Castle Biosciences from $33.00 to $37.00 and gave the company a “sector outperform” rating in a research note on Friday, March 1st. Finally, KeyCorp increased their price objective on Castle Biosciences from $25.00 to $28.00 and gave the stock an “overweight” rating in a research report on Friday, March 1st.

View Our Latest Analysis on Castle Biosciences

Castle Biosciences Trading Down 1.2 %

Shares of NASDAQ:CSTL opened at $24.21 on Friday. The business’s 50 day simple moving average is $22.16 and its 200 day simple moving average is $21.55. Castle Biosciences, Inc. has a 1 year low of $9.26 and a 1 year high of $26.70. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.25 and a quick ratio of 9.02. The company has a market capitalization of $668.37 million, a P/E ratio of -21.05 and a beta of 0.93.

Castle Biosciences (NASDAQ:CSTLGet Free Report) last released its earnings results on Thursday, May 2nd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.28. Castle Biosciences had a negative return on equity of 7.91% and a negative net margin of 12.28%. The company had revenue of $72.97 million for the quarter, compared to analyst estimates of $68.34 million. On average, research analysts anticipate that Castle Biosciences, Inc. will post -2.02 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Derek J. Maetzold sold 1,947 shares of the business’s stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $20.35, for a total value of $39,621.45. Following the completion of the transaction, the insider now directly owns 65,418 shares in the company, valued at approximately $1,331,256.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, insider Derek J. Maetzold sold 1,947 shares of Castle Biosciences stock in a transaction on Friday, April 12th. The stock was sold at an average price of $20.35, for a total value of $39,621.45. Following the transaction, the insider now owns 65,418 shares in the company, valued at approximately $1,331,256.30. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Daniel Bradbury sold 23,323 shares of the business’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $24.64, for a total value of $574,678.72. Following the transaction, the director now directly owns 9,981 shares of the company’s stock, valued at approximately $245,931.84. The disclosure for this sale can be found here. Insiders have sold 74,100 shares of company stock worth $1,644,630 over the last ninety days. Corporate insiders own 7.20% of the company’s stock.

Castle Biosciences Company Profile

(Free Report)

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.

See Also

Want to see what other hedge funds are holding CSTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Castle Biosciences, Inc. (NASDAQ:CSTLFree Report).

Institutional Ownership by Quarter for Castle Biosciences (NASDAQ:CSTL)

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.